Home Sitemap Contact us Accessibility Statement Top of the page
  • CINQAERO®

    CINQAERO®▼

    (reslizumab)

Prescribing CINQAERO®

CINQAERO® (reslizumab) is an add-on therapy for the management of severe eosinophilic asthma.1

Available as:

  • CINQAERO® 10mg/mL concentrate for solution for infusion; it is licensed for adults aged 18 years and over.1

Therapeutic indications 

CINQAERO® is indicated as add-on therapy in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another medicinal product for maintenance treatment.1


Facts about CINQAERO®

  • The annual rate of asthma exacerbations was reduced by 54% in patients receiving reslizumab compared to placebo.2
  • Improvement in FEV1 was significantly greater in patients receiving reslizumab compared to placebo (0.22 vs 0.12 at Week 52; p<0.0001).2
  • Significantly reduced the rate of clinical asthma exacerbations*1,2
  • Significantly improved lung function (FEV1) from Week 4 through to Week 52*1,2
  • Significantly improved quality of life (AQLQ) from week 16 through to Week 52*1,2

*Data from two randomised, double-blind, placebo-controlled clinical trials (n=953) in a targeted patient population with inadequately controlled asthma and elevated blood eosinophils (≥400 cells/μL). Patients received either placebo (n=476) or CINQAERO® (n=477). Both treatments were added to standard of care.1,2

[Pooled analysis of two studies where patients with blood eosinophils ≥400 cells/µL and one or more exacerbations in the previous year were randomised to reslizumab 3mg/kg by i.v. infusion (n=477) or placebo (n=476) every four weeks.]

About CINQAERO®

CINQAERO® is provided as a concentrate for solution for infusion, in a single-use vial.1

Reslizumab is a humanised monoclonal antibody that binds specifically to interleukin-5, a major cytokine responsible for the differentiation, maturation, recruitment and activation of eosinophils  - which have a role in inadequately controlled asthma.1,2

CINQAERO® targets IL-5 to reduce eosinophilic airway inflammation and reduce blood eosinophils.1,2

Marketing Authorisation

Teva Pharma B.V.
Swensweg 5,
2031GA Haarlem
The Netherlands

Marketing Authorisation number(s)

  • EU/1/16/1125/001
  • EU/1/16/1125/002

Resources for CINQAERO®

You can ask a question, request to see a representative from Teva, or report a side effect.

Ask a Question Request a Rep Report Suspected Side Effect

Medicine supporting documentation for CINQAERO®

Teva's Respiratory Educational Programme

Let's Talk Respiratory is our educational programme of supportive materials, resources and some of the latest news in respiratory for both you and your patients. Our aim is to support you and encourage you, help empower patients and to make a real difference to the lives of those living with asthma and COPD.

1. CINQAERO® Summary of Product Characteristics. Teva Pharmaceuticals Europe B.V.

2. Castro M, Zangrilli J, Wechsler ME et al. Lancet Respir Med, 2015; 3: 355-66.


Teva UK Limited

Are you a healthcare professional?

To access this section of the Teva UK Limited website you need to be a member of the healthcare profession because the materials included in this area of our website are specifically prepared for that audience only.
To understand why that is - please visit: Working in a regulated environment

Please click on the appropriate button below to confirm that you are healthcare professional.
If you are not a healthcare professional, you will be taken to an area of the website that is appropriate for you.

I am a